A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Inclusion Criteria: * Participant has signed, dated and received a copy of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF). * Participant is aged 18 to 85 years of age (inclusive) at the time of signing the ICF. * Participant has physician diagnosed CRSwNP for at least 6 months prior to Visit 1 that fulfills all of the following: * Severity consistent with need for surgery as defined by an endoscopic bilateral NPS of at least 5 out of 8 and a minimum score of 2 in each nasal cavity at Visit 1 based on central reading, as well as reconfirmed at Visit 2 based on local reading. * Average NCS greater than and equal to (\>=) 2 over 14 days before Visit 2. * Ongoing symptoms of CRSwNP for at least 8 weeks prior to Visit 1 such as rhinorrhea and/or reduction in smell. * Participant has at least one of the following: * In the 24 months prior to Visit 1, had a documented exacerbation of nasal polyposis requiring treatment with systemic corticosteroid. * A medical contraindication/intolerance to systemic corticosteroid. * Had prior surgery for NP (cannot be within 6 months prior to Visit 1 * Stable standard of care treatment for CRSwNP for at least 30 days prior to Visit 1. * At Visit 2, at least 21 days of background mometasone furoate nasal spray (MFNS) (or equivalent) background therapy. * \>=70 percent (%) dosing compliance for MFNS (or equivalent) in the 14 days prior to Visit 2. * Agrees to follow…